Search Results

Dr. GPCR is proud to partner with the 5th Annual GPCRs-Targeted Drug Discovery Summit. This post is your one-stop hub — agenda highlights, who's attending, our exclusive discount code, and speaker interviews as they go live. Why the GPCR Drug Discovery Field Is Converging in Boston The GPCR field is in a genuinely exciting moment. Not hype — momentum. The human genome encodes ~800 GPCRs, yet only around 15% are currently targeted by approved drugs — leaving an enormous and largely untapped therapeutic opportunity. New structural tools, AI-driven design pipelines, and a growing number of programs moving into the clinic are redefining what's possible across modalities and indications. Pharma interest is high, as reflected in major deals across the space. The 5th Annual GPCRs-Targeted Drug Discovery Summit is the industry-led meeting dedicated entirely to GPCR drug discovery — across small molecules, peptides, and antibodies, and across indications. This year's program reflects where science is actually heading. Dr. GPCR founder Dr. Yamina Berchiche will be there — if you're attending, reach out to connect. Who's at the GPCR-Targeted Drug Discovery Summit 2026 The meeting brings together 80+ senior leaders from biotech and pharma to advance GPCR programmes from discovery through translation — experts in GPCR biology, structural biology, computational design, pharmacology, and translational strategy. Companies already confirmed to attend include: Abalone Bio · AbbVie · Biagon · Biolexis Therapeutics · Confo Therapeutics · Eli Lilly · GSK · Nabla Bio · Northeastern University · Nxera Pharma · OMass Therapeutics · Superluminal Medicines · Tectonic Therapeutics · and many more. GPCR Drug Discovery Agenda Highlights: What's New in 2026 This year's summit runs across three days — an AI & ML Focus Day on April 28, followed by two conference days — and the program spans the full breadth of the field. Biased Signaling, Endosomal Pathways & GPCR Signaling Complexity How do we disentangle intrinsic, system, and kinetic bias in a way that actually predicts clinical outcomes? Sessions from InterAx Biotech, Northeastern University, and Function Therapeutics dig into this — moving beyond static potency and efficacy to mechanistic signatures that guide drug design. A panel discussion will tackle best practices for measuring GPCR signaling bias in vitro and what that means for in vivo and clinical translation. AI & ML in GPCR Drug Discovery A dedicated focus day brings together teams from Nabla Bio, Abalone Bio, Biagon, Iambic Therapeutics, Lembas, and Eli Lilly. These aren't primers on AI — they're teams presenting real workflows and real data, covering generative antibody design, dynamic conformational modeling, federated computing platforms, and predictive simulations that shorten discovery timelines. Antibodies, Cyclic Peptides & Allosteric Modulators Nine or more presentations on non-small molecule approaches — including agonistic antibodies, GPCR-directed ADCs, orally available cyclic peptides, and allosteric probes for Class B GPCRs. Companies presenting include Skymab Biotherapeutics, Confo Therapeutics, GSK, Metaphore Biotechnologies, and Abilita Therapeutics. Translational Stories & Clinical Data OMass Therapeutics on long-residence MC2R antagonists. Tectonic Therapeutics on engineering a long-acting relaxin for pulmonary hypertension. Kainova Therapeutics presenting Phase 1 outcomes for their EP4 receptor antagonist in solid tumors. Alphamol on Phase 1 results from an orphan GPCR program pursued against industry skepticism. 🎥 Speaker Spotlight: GPCR Drug Discovery Experts to Watch Dr. Will Barnes is Executive Director and Head of GPCR Biology at Iambic Therapeutics, where he leads AI-driven structural modeling for GPCR drug discovery. With a PhD studying histamine receptors and a postdoc with Bob Lefkowitz at Duke, he brings two decades of industry experience — and a GPCR program in every chapter of it. Watch our conversation below. Chris Dockendorff is the founder of Function Therapeutics, a small biotech on the University of Wisconsin–Milwaukee campus working primarily on protease-activated receptors. A medicinal chemist by training, he has spent his career moving between academia and industry, building small molecules that solve real problems for biologists. At the 5th GPCRs Targeted Drug Discovery Summit, Chris is leading a roundtable on biased signaling, endosomal signaling, and GPCR oligomerization. Watch our conversation below. Register for the GPCR Drug Discovery Summit — Exclusive DrGPCR Discount Use the exclusive DrGPCR discount code DRGPCR10 at checkout for 10% off registration. Early bird pricing also runs through March 6, saving up to $600 off the door price — so don't wait. 🔗 Register here 🔗 Explore the full event guide 🔗 Contact the event team for your discount The 5th Annual GPCRs-Targeted Drug Discovery Summit takes place April 28–30, 2026 at The Colonnade, 120 Huntington Avenue, Boston, MA.

The community is gathering. No agenda. No presentations. Just your people, in one room. Some of the best conversations in GPCR science don't happen at the podium. They happen in the hallway between sessions, at the coffee station, or in the ten minutes after a talk when someone finally says what they actually think. The problem is those moments are rare, rushed, and easy to miss. That's why we created GPCR Happy Hour. On April 29th, the Dr. GPCR community is gathering in Boston for an informal evening of real conversation. No presentations. No panels. No agenda. Just GPCR scientists in a room together, with food, drinks, and two hours to have the discussions that conferences don't make space for. The evening takes place at Pressed Cafe, 105 Huntington Ave — steps from The Colonnade, where the 5th Annual GPCRs-Targeted Drug Discovery Summit  is bringing together 80+ senior leaders across GPCR-focused biopharma from April 28–30. If you're attending the summit, join us right after Conference Day One wraps. If you're local to Boston, this is your chance to meet the community in person. Space is limited to 50 scientists. Food and one drink ticket included. Cash bar available. Register your spot here. Why we keep it small Fifty people is a deliberate choice. It's the size where you can actually talk to everyone in the room. Where a conversation that starts with one person pulls in three others. Where you walk away with a handful of connections that actually go somewhere, not a stack of business cards you'll never follow up on. This is not a mixer. It's not a corporate reception. It's a gathering of people who already share something (a deep commitment to GPCR science) even if they're meeting for the first time. Who's making the GPCR Happy Hour evening possible GPCR Happy Hour is made possible by four companies that didn't just want to reach GPCR scientists, they wanted to be part of bringing the community together in person. NIS | Founding Co-Host NanoImaging Services (NIS) is a US-based structural biology partner offering a fully integrated gene-to-structure platform, with facilities in San Diego, CA and Woburn, MA. Through their acquisition of Proteos, NIS combines two decades of recombinant protein production expertise, across mammalian, insect, and bacterial expression systems with high-resolution cryo-EM capabilities, including epitope mapping and structure determination of challenging targets like GPCRs and membrane protein complexes. NIS is the kind of partner that understands what GPCR discovery actually requires at the structural level. Want to learn more about NIS? Watch my conversation with their CSO Giovanna Scapin Revvity | Founding Co-Host Revvity is a global leader in life science innovation, delivering tools and technologies that bridge the gap between discovery and real-world impact. With decades of expertise and an unwavering focus on precision, Revvity empowers scientists to simplify complex workflows, accelerate discovery, and drive breakthroughs in drug development, diagnostics, and disease biology. Whether you're decoding signaling pathways or designing the next generation of therapeutics, Revvity brings the kind of platform-level support that serious GPCR programs depend on. EuroscreenFast EuroscreenFast has been a pioneer in GPCR science for more than 30 years,. The first company to offer access to recombinant GPCR assays. Today, their catalogue includes over 1,000 functional assays representing more than 550 GPCR and other targets, trusted by therapeutic developers worldwide for affinity, potency, efficacy, and functional selectivity studies. Their deorphanisation track record (17 identified natural receptor-ligand pairs) speaks to the depth of their scientific investment in the field. Montana Molecular Montana Molecular is a leader in advanced GPCR assay technologies and services, combining genetically encoded fluorescent biosensors and BacMam gene delivery tools to measure the spatial and temporal signaling properties of drug candidates in living cells. Their platform delivers kinetic profiles that reliably inform decisions and reduce the risk and cost of developing new drugs, exactly the kind of intelligence GPCR programs need at the lead selection stage. Who should come This evening is open to pharma, biotech, academia, and students. If you work in GPCR science (or plan to) you belong in this room. Whether you've been following Dr. GPCR online for years or you're hearing about us for the first time, walk in. You already belong. Employees of service providers or CROs: please inquire about co-hosting and vendor options at Hello@DrGPCR.org . The details 📅 Wednesday, April 29, 2026 ⏰ 6:00 PM – 8:00 PM 📍 Pressed Cafe, 105 Huntington Ave, Boston, MA (A two-minute walk from The Colonnade) Food and one drink ticket included. Cash bar available after. Space is limited to 50 scientists — registration is required. This event is open to pharma, biotech, academia, and students. Employees of service providers or CROs: please inquire about co-hosting and vendor options. Register your spot. We'll see you April 29th.

It's spring break at Dr. GPCR — a quieter week, and a good moment to look at what this community is examining next. Five live Masterclasses are scheduled before summer break. Two Partner Webinars are lining up. And two recent sessions are moving into the on-demand library next week. Taken together, the lineup spans biophysics, kinetics, spatial biology, subcellular regulation, and program building. Five sessions examining GPCR science past the equilibrium snapshots, where and when receptors signal, how kinetics shape drug action, and how all of it translates into programs. Coming to the GPCR Masterclass On-Demand Library Two sessions from April are moving into the Premium Masterclass library next week: Bryan Roth on intracellular allosteric modulators as molecular glues — recorded April 9. Terry Hébert on iPSC-derived systems for GPCR signaling and translation — recorded April 16. Explore the library ➤ Five Live GPCR Masterclasses Before Summer All included in Premium , each one a direct scientific exchange with a leading scientist, with full replay access afterward. Sam Hoare  — How Signaling Kinetics Shapes GPCR Drug Action. May 14. Sudarshan Rajagopal  — The Spatiotemporal Revolution in GPCR Biology. May 21. Andrew Tobin  — How to Build Breakthrough GPCR Programs. June 4. Jakob Höppner  — Subcellular Regulation of PTH1R Signaling. June 11. Dmitry Veprintsev  — Biophysical Approaches to Study Orphan GPCR Ligand Binding and Signalling. June 18. More live Masterclasses coming in the fall. Learn more about Live Masterclasses ➤ Partner Webinars Eurofins DiscoverX (Dr. Terry Kenakin, invited speaker)  — Biased signaling. GeneTex (Dr. Alex Ball)  — A reagent gap that holds back the biology. Details coming soon. Next Week in Boston The Dr. GPCR community gathers in person next week. GPCRs Targeted Drug Discovery Summit  — April 28–30. What to expect and how to register ➤ GPCR Happy Hour  — April 29. Come find us ➤ About Dr. GPCR Dr. GPCR is the intelligence and community for GPCR scientists. Premium members have full access to the pre-summer Masterclass lineup, the live sessions, and the expanding on-demand library. Where to find your Premium content As a Premium member, everything is under the Premium  menu in the top navigation — Live Masterclass, Masterclass On Demand, Weekly News, Job Listings, GPCR Events, Ask the Ecosystem, Ecosystem Members, and Your Feedback. Bookmark ecosystem.drgpcr.com  and you're one click away from all of it. Join Premium ➤ Try Premium for 14 days — $49 ➤

Dr. GPCR Podcast - The Voice of the Community Whether you’re a scientist, student, or just curious, you’ll hear about discoveries, career stories, and the latest GPCR news. Jump in and get inspired! Strategic Partners Latest Podcast Episodes Select by Guest Name 2026-04-29 2026-03-04 2025-12-17 2025-11-05 2026-04-01 2026-02-18 2025-12-03 2025-10-22 2026-03-18 2026-02-04 2025-11-19 2025-09-22 1 2 3 4 5 1 ... 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 ... 16 Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player Listen and subscribe where you get your podcasts

Explore the world of GPCRs with Dr. GPCR Podcast! Join industry leaders as they share insights, stories, and groundbreaking discoveries, enriching our understanding of GPCRs. Delve into the science behind these vital components shaping our collective knowledge. Welcome to the Dr. GPCR Podcast - The Voice of the Community Conversations with the world’s leading GPCR scientists. Exploring discoveries, careers, and ideas shaping human health. In each episode, we sit down with leading experts to explore their career journeys, groundbreaking discoveries, and the impact of their research on our shared understanding of GPCR biology. Launched at the height of the pandemic, the Dr. GPCR Podcast was created with three goals: Share discoveries – Highlight the latest advances in the GPCR field. Amplify voices – Provide scientists a platform to showcase their work. Inspire the future – Motivate the next generation to pursue GPCR research. At its core, Dr. GPCR’s mission is simple yet ambitious: to bring the GPCR community together - across borders and disciplines - to connect, exchange, and collaborate in order to improve human health through a deeper understanding of GPCR biology. Latest Podcast Episodes More podcast episodes Dr. GPCR Podcast Audience Survey We are currently planning our next season and need your help. This short survey will help us understand your needs to bring you exciting and informative content. We also know that you are busy, which is why we designed this short survey that should take you 5 minutes. Fill out this form Be our Guest In each episode, we chat with an expert about their career trajectory, discoveries, and how their research contributed to the shared pool of knowledge about GPCR biology. We’d love to have you on our podcast. To be a guest, fill out the form below, and we’ll be in touch in 48 hours. Fill out this form What others are saying about this podcast "You made it a very comfortable and engaging experience, and it felt like we were chatting over coffee — Yamina thoughtfully guided our chat throughout." Anita Nivedha I think it's really well done. I'm genuinely interested to see how it evolves and grows over time, as I feel it has the potential to develop into something even more impactful. Anonymous This came at just the most perfect time. I hadn't heard a scientific talk outside my lab since February and was starved to hear someone else talk passionately about GPCRs. I've listened to the episodes multiple times and it's just like being at a conference getting new ideas. I just couldn't be happier y'all created this podcast. Anonymous Great initiative, thanks. Carrier paths, choosing research topics, switching fields, late start, failures and successes. Anonymous I enjoy the breadth of questioning that goes beyond just the science, and reveals a bit about the scientists as individuals/mentors/people. Anonymous Really enjoyable science podcast! Dr. Yamina Berchiche interviews leading GPCR scientists on this vibrant, entertaining podcast. I really appreciate the way the podcast educates and mentors, particularly towards junior scientists but also to the community as a wholen Yamina is a great interviewer, getting insight and personal history from her guests. Am very grateful for Dr GPCR livening up the week in these difficult times! Sam @Pharmamechanic Listen and subscribe where you get your podcasts

A conversation with Dr. Tore Bengtsson on β₂-adrenergic receptor signaling, muscle metabolism, and how GPCR pharmacology can lead to new therapies for metabolic disease. << Back to podcast list Strategic Partner(s) Dr. Tore Bengtsson: Rethinking β₂-Adrenergic Signaling in Metabolic Disease Scientific Abstract This conversation with Dr. Tore Bengtsson , professor of physiology at Stockholm University, explores how β-adrenergic receptor signaling can be reimagined to address metabolic disease, muscle physiology, and energy balance. Dr. Bengtsson’s research spans sympathetic nervous system signaling, brown adipose tissue biology, and skeletal muscle metabolism—fields deeply connected to obesity, type 2 diabetes, and metabolic health. A central theme of the discussion is the pharmacology of the β₂-adrenergic receptor , a GPCR traditionally associated with bronchodilation but increasingly recognized for its broader physiological roles. Dr. Bengtsson describes how classical β₂ agonists stimulate muscle growth and metabolic changes but are limited by receptor desensitization. His work focuses on developing novel β₂-adrenergic ligands that selectively engage signaling pathways without triggering rapid desensitization, enabling sustained metabolic effects. The conversation also examines how GPCR signaling is far more complex than a single downstream pathway. Instead, receptors integrate multiple signaling outputs, temporal dynamics, and interactions with other pathways to shape physiological outcomes. Dr. Bengtsson discusses how understanding this signaling complexity opens opportunities to design drugs that promote beneficial metabolic responses such as muscle growth and increased energy expenditure. Listeners gain insight into how basic GPCR pharmacology can translate into therapeutic strategies targeting metabolism, aging, and metabolic disease. About the Guest Dr. Tore Bengtsson is a professor of physiology at Stockholm University whose research focuses on sympathetic nervous system signaling, metabolic regulation, and skeletal muscle physiology. His work investigates how β-adrenergic receptors regulate energy metabolism, muscle growth, and glucose homeostasis. Dr. Bengtsson began his research career studying brown adipose tissue under the mentorship of Dr. Barbara Cannon and Dr. Jan Nedergaard, pioneers in thermogenesis research. His laboratory now explores how β₂-adrenergic receptor signaling can be manipulated to influence metabolism and muscle physiology. He is also an entrepreneur and founder of biotechnology companies translating GPCR pharmacology into therapeutic development. Scientific Themes of the Conversation β-adrenergic receptor pharmacology and signaling bias Sympathetic nervous system control of metabolism Brown adipose tissue and thermogenesis Skeletal muscle metabolism and glucose homeostasis GPCR signaling complexity and pathway selectivity Translating receptor pharmacology into metabolic therapeutics Key Insights from the Conversation A Childhood Physiological Experiment Sparked a Scientific Career Dr. Bengtsson recounts a formative experience when his father pushed him into icy water as a child to demonstrate survival in cold conditions. The intense physiological response—an adrenaline surge and rapid adaptation to cold—sparked his lifelong fascination with sympathetic nervous system signaling and stress physiology. Stress Is Not Always Negative A recurring theme in the discussion is that physiological stress is often misunderstood. Short bursts of stress—whether exercise, cold exposure, or sympathetic activation—can trigger adaptive responses that improve metabolic function and resilience. Muscle Is Central to Metabolic Health While brown fat has received considerable attention, Dr. Bengtsson emphasizes the dominant role of skeletal muscle in metabolic regulation. Approximately 75% of glucose disposal occurs in muscle, making muscle physiology central to metabolic diseases such as type 2 diabetes. Classical β₂ Agonists Have a Fundamental Limitation Traditional β₂-adrenergic agonists can stimulate muscle growth and fat loss but lose effectiveness over time due to receptor desensitization. This pharmacological limitation prevents their long-term use for metabolic therapies. GPCRs Do Not Produce a Single Signal Dr. Bengtsson highlights that GPCR signaling is inherently multidimensional. Activation of a receptor can generate multiple signaling pathways, and different ligands can bias signaling toward specific outcomes. Understanding this complexity is essential for modern drug discovery. Absence of a Signal Can Be a Discovery One of Dr. Bengtsson’s key scientific breakthroughs came from an unexpected experimental result: glucose uptake without detectable cAMP signaling. Rather than dismissing the result as an error, this observation led to the realization that β₂ signaling could be separated into distinct pathways. Scientific Discovery Requires Intellectual Independence Dr. Bengtsson advises young scientists to shift from passively following instructions to actively questioning experiments and interpretations. True scientific thinking begins when researchers take intellectual ownership of the questions they pursue. Episode Timeline 00:00 Introduction and research focus of Dr. Bengtsson 03:00 A childhood experiment that sparked interest in physiology 07:00 Cold exposure, sympathetic signaling, and brown fat research 10:00 β₂-adrenergic receptors and muscle physiology 15:00 Exercise, metabolism, and pharmacological modulation of muscle growth 17:30 Early research on brown adipose tissue and thermogenesis 22:30 Translating academic discoveries into biotech companies 25:00 GPCR signaling complexity and biased signaling 36:00 A key experimental observation leading to a new drug concept 38:30 Advice for young scientists and intellectual independence Selected Quotes “You will not know what happens before you do the experiment.” “People think a receptor produces one signal. In reality, a receptor produces many signals.” “Sometimes the most important discovery is when a signal is missing.” “You have to move from being told what to do to thinking for yourself.” Full Transcript (Formatted for readability — full transcript preserved) Yamina Berchiche: Hello, everyone. This is Yamina from Dr. GPCR. And today I'm very excited to have with me Dr. Tore Bengtsson. Dr. Bengtsson: Tore Bengtsson. And you got it right. Yamina Berchiche: I'm happy to have you on. For those who don't know, we've been chasing each other and postponing this conversation several times. I'm very excited that we're finally able to do it today. Dr. Bengtsson: Thank you. I'm very happy to be here. Yamina Berchiche: Let's start at the beginning. Could you introduce yourself and tell us about your research? Dr. Bengtsson: I'm a professor in physiology at Stockholm University. I've been working with pre-diabetes, type 2 diabetes, obesity, and the mechanisms behind these diseases for about 25 years. I'm especially interested in β-adrenergic receptors because I believe they regulate far more physiological processes than people typically assume. I'm also an entrepreneur. I've started several companies. One is Sigrid Therapeutics, which focuses on digestion and metabolic regulation. Another company, Atrogi, is based on our research on β₂-adrenergic receptors and the development of new drugs. We’ve already completed Phase I clinical trials and are preparing for Phase II. Yamina Berchiche: If you were not a scientist, what would you be doing? Dr. Bengtsson: I think I might have been a historian or a writer. I like storytelling. I'm very interested in Viking runes and ancient rune stones in Scandinavia. I can actually read runic inscriptions, and I find it fascinating to interpret what these stones tell us about history. Yamina Berchiche: How did you become a scientist? Dr. Bengtsson: I'll tell you a story I don't share very often. When I was about ten years old, I lived on an island in the Stockholm archipelago. My father and I went ice skating frequently during the winter. One summer he asked me: “What happens if you fall through the ice?” I said I didn't know. He replied: “We should test it.” Months later, during winter, he cut a hole in the ice. I asked what he was doing. He said he was catching a big fish. Suddenly he pushed me into the icy water. I went under, looked up at the hole in the ice, and quickly swam out. I remember the intense adrenaline surge. My body reacted instantly. I wasn't even cold at first. Walking home later I started to freeze, but in that moment I experienced a powerful physiological response. That event sparked my lifelong fascination with sympathetic nervous system activation. Yamina Berchiche: So your father pushed you into science quite literally. Dr. Bengtsson: Yes — and into physiology. Yamina Berchiche: And that connects directly to your later work on brown fat and sympathetic signaling. Dr. Bengtsson: Exactly. I've spent many years studying brown adipose tissue and how sympathetic activation stimulates thermogenesis. Later I became increasingly interested in skeletal muscle metabolism and how β₂-adrenergic signaling affects muscle growth and glucose metabolism. Yamina Berchiche: Could you talk about how β₂-adrenergic signaling relates to muscle growth? Dr. Bengtsson: For many years it's been known that β₂ agonists can stimulate muscle growth and reduce fat. This has been observed in athletes and even in livestock production. But traditional β₂ agonists lose effectiveness over time because the receptor becomes desensitized. The body adapts, requiring higher doses. That makes them unsuitable as long-term therapeutic drugs. So about 15–20 years ago I began working on the idea that we need a new type of β₂ agonist—one that activates the receptor differently and avoids desensitization. That’s what we’ve now achieved with new compounds that stimulate the receptor in a novel way. Yamina Berchiche: You mentioned something very important earlier: GPCRs don’t produce a single signal. Dr. Bengtsson: Yes. Traditionally people thought receptor activation leads to one downstream pathway. But GPCRs activate multiple signaling pathways simultaneously. Different ligands can bias signaling toward different pathways. That means we can design compounds that favor beneficial physiological responses while avoiding unwanted effects. That is exactly what makes GPCR pharmacology so fascinating and powerful. Yamina Berchiche: You mentioned an important experimental moment that led to your drug concept. Dr. Bengtsson: Yes. A doctoral student ran an experiment measuring glucose uptake. The compound produced strong glucose uptake but almost no cAMP signaling. She thought the experiment had failed. But I realized this might be something important: glucose uptake without cAMP. And that turned out to be correct. That observation opened the door to separating signaling pathways and designing new β₂ ligands. Yamina Berchiche: What advice would you give to young scientists? Dr. Bengtsson: Young scientists often follow instructions without asking why. Real science begins when you take control of the question. You must move from being told what to do to thinking independently. You have to be in the driver's seat of your own thinking. Yamina Berchiche: That’s a powerful message. Dr. Bengtsson: And another lesson I learned from my wife: success often depends not just on knowledge but on understanding how other people think. Science is not just experiments. It's communication, persuasion, and collaboration. Yamina Berchiche: Dr. Bengtsson, thank you very much for the conversation. Dr. Bengtsson: Thank you. This was great. Yamina Berchiche: Bye. Dr. Bengtsson: Bye-bye. Upcoming Live Expert Sessions ➚ 🔒Explore the Full Masterclass ➚ Unlock the Full Dr. GPCR Learning Ecosystem ✔ Full Masterclass library ✔ Terry's Pharmacology Corner ✔ Advanced GPCR courses ✔ Scientific discussions → Become Premium Recent Podcast Articles Asking Better Questions in Science: A Practical Guide for Emerging Researchers When the Islet Lit Up: Advancing GPCR Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>